Home » Posts tagged 'Alan Green CEO Brand Communications'
Tag Archives: Alan Green CEO Brand Communications
Sitting Astride a Tax Free Fortune | Investing Into Classic Motorcycles | Alan Green talks to Paul Jayson
Sitting Astride a Tax Free Fortune – Investing Into Classic Motorcycles. Investor relations and PR guru Alan Green is CEO of Brand Communications, but also happens to be a lifelong motorcycle and classic bike enthusiast.
In a recently recorded interview, Alan and Paul Jayson take a look at the services provided by his company, The Motorcycle Broker. Paul expands on the substantial tax free returns on offer from certain classic motorcycles, and runs through some examples, including a Kawasaki Z1 900, an Allen Millyard special Kawasaki 1000, and an MV Agusta 750s. Alan and Paul then look at the rapidly appreciating Honda CBX 1000, after which Paul looks at three rare Ducati motorcycles that have provided spectacular investment returns – the Ducati 750 Sport Z Stripe, the green frame Ducati 750SS and the Carl Fogarty World Superbike winning Ducati 916.
The episode finishes with Paul providing some takeaway points for investors to consider when purchasing a classic motorcycle.
Brand CEO Alan Green talks to Paul Jayson, better known as The Motorcycle Broker. Alan begins by outlining his lifelong interest in motorcycles, before Paul expands on the services provided by TMB.
Paul then expands on how classic motorcycles can provide substantial tax free returns, and runs through some examples, including a Kawasaki Z1 900, an Allen Millyard special Kawasaki 1000, and an MV Agusta 750s.
Alan and Paul then look at the rapidly appreciating Honda CBX 1000, after which Paul looks at three rare Ducati motorcycles that have provided spectacular investment returns – the Ducati 750 Sport Z Stripe, the green frame Ducati 750SS and the Carl Fogarty World Superbike winning Ducati 916.
The episode finishes with Paul providing points for investors to consider when purchasing a classic motorcycle.
Alan Green talks to Venture Life Group (VLG) CEO Jerry Randall about the company’s interim results.
Jerry goes through the numbers and commercial developments for the period, before discussing post period-end developments, including an independent study at Cardiff University on the effects on Dentyl Dual Action mouthwash on patients affected by COVID-19.
Jerry explains the resilience and adaptability of the Venture Life business model in countering the challenge of the COVID lockdown, and highlights how the group’s strong cash position will fund any future acquisitions.
Alan Green talks to Venture Life Group (VLG) CEO Jerry Randall about today’s trading update. Jerry provides an overview of the VLG offering, and then discusses the financial and commercial highlights in today’s statement. Looking forward Jerry covers VLG’s strong financial position, and how non-dilutive funding will be used for further acquisitions, some of which (subject to Covid restrictions), may arrive before Christmas 2020.
Jerry also provides key points for investors going forward.
1) Earnings growth, profitability and strong cashflow
2) Manufacturing capacity – following investment into the manufacturing and distribution, VLG can now increase it’s capacity by 50%.
3) Improving liquidity for shareholders. The appointment of N+1 Singer has improved liquidity and volumes in the market
Alan Green talks Jerry Randall, CEO of Venture Life Group (AIM: VLG). Jerry provides an overview of the company operating structure and strategy, and then covers today’s trading statement, going into detail on the very strong trading that will see the company ‘comfortably exceed market expectations’ for the year. Jerry covers the group’s commercial relationships and partners, provides detail on the strong funding position and provides an outlook for value inflection points going forward.
It’s been an exceptionally busy few months for Open Orphan (ORPH) and its Executive Chairman Cathal Friel.
Since reversing into Venn Life Sciences last summer, Open Orphan has set it’s sights on a series of acquisitions to forge a specialist pharmaceutical services group with a focus on orphan drugs. In raising the money to complete the Venn Life Sciences and recent hVIVO acquisitions, Friel has invested over £2m of his own money through his investment vehicle Raglan Capital into Open Orphan. His investments are locked in until three years after the IPO in June 2019.
In 2018, over 50% of new FDA approved drugs were classed as ‘orphan’, i.e. treat rare diseases.
With this in mind, Friel and his team have constructed a vehicle to acquire and consolidate a number of smaller companies into a larger profitable pharma services company. Within this there is Open Orphan Genomic Health Data, using AI tools to build a valuable database of patient information using a low cost data collection methodology.
In the run up to the end of 2019, ORPH struck several three year contract agreements and collaborations lucrative partnership agreements and collaborations, most notably with French pharma giant Ipsen Group, Japanese pharma company Carna and a Tier 1 German pharma company as part of moving the original Venn business away from short term ad-hoc contracts towards longer more sustainable contracts.
The acquisition promised at Open Orphan’s launch last summer came to fruition in December, when the company announced the acquisition of hVIVO, a world leader in the provision of viral challenge study services to companies developing vaccines for viruses.
The deal offered 2.47 shares for each hVIVO share, providing its shareholders with a 33% uplift. Open Orphan also broke the mould by moving fast in a slow moving sector as this takeover was recorded as one of the fastest in 7 years for the London market, completing as it did in just 38 days. More importantly, the economies of scale the merger delivers greatly broadens Open Orphan’s in-house clinical offering and opportunities to commercialise the existing deal pipeline.
Both Venn and more importantly hVIVO had been chronically loss making, however given the compelling synergies, the Open Orphan team led by Friel are optimistic that the enlarged Group will be profitable by June 2020 if not before.
To maximise on the opportunities generated by the acquisition, a further £5.3m fundraise was completed at the end of January 2020, conducted at a small premium to market price and with a minimum fundraise of £2.5m once again underwritten by Friel’s investment vehicle. The raise was oversubscribed, predominantly funded by institutional investors and at a good premium to the IPO fundraise in June 2019. Added to this, Friel personally invested £300k.
As part of the hVIVO acquisition, Open Orphan now owns the largest quarantine facility in N Europe, with 24 quarantine bedrooms at Queen Mary’s Hospital in London.
As things currently stand, this facility may potentially be used for ill patients patients during the current Coronavirus crisis that is gripping China and slowly spreading to other countries.
Professor John Oxford, one of the original founders of hVIVO is also a world-leading expert on Coronavirus and virology. In this capacity he has appeared across numerous TV and radio programmes over the past week, and is also an advisor and consultant to Cathal Friel and the enlarged Open Orphan Group.
The coming days will see more information emerge about Open Orphan and hVivo’s capabilities surrounding virology, vaccines and the quarantine facility.
To keep up to speed with this fast moving company, the latest copy of the Open orphan investor presentation is now available to view on https://www.openorphan.com/investors/reasons-invest.
Alan Green – February 2020
Alan Green CEO of Brand Communications discusses Feedback #FDBK and gives the bull case for Metro Bank #MTRO
Brand CEO Alan Green talks Open Orphan #ORPH, Volga Gas #VOLG, Thomas Cook #TCG & IMC Exploration #IMC on Vox Markets podcast
Alan Green, CEO of Brand Communications talks about: Open Orphan #ORPH Volga Gas #VGAS Thomas Cook #TCG IMC Exploration #IMC with Justin Waite on the Vox Markets podcast. Interview is 7 minutes 29 seconds in.
Brand CEO Alan Green talks about: Bidstack #BIDS Tiziana Life Sciences #TILS RA International #RAI IMC Exploration #IMCP Thomas Cook Group #TCG
Alan Green CEO of Brand Communications talks about: Bidstack #BIDS Tiziana Life Sciences #TILS RA International #RAI IMC Exploration #IMCP Thomas Cook Group #TCG
(Interview starts at 31 minutes 48 seconds)